InsiderSignal.AI

InsiderSignal.ai

KYMR - Kymera Therapeutics, Inc.

Insider Sale by Chadwick Jeremy G (COO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

5 days ago, Chadwick Jeremy G, serving as COO at Kymera Therapeutics, Inc. (KYMR), sold 22,240 shares at $85.43 per share, for a total transaction value of $1,900,048.00. Following this transaction, Chadwick Jeremy G now holds 61,202 shares of KYMR.

This sale represents a 27.00% decrease in Chadwick Jeremy G's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, March 31, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, April 1, 2026, 1 day after the trade was made.

Kymera Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Chadwick Jeremy G

Chadwick Jeremy G

COO

Jeremy Chadwick, Ph.D. is the Chief Operating Officer of Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in targeted protein degradation[[1]](https://www.globenewswire.com/news-release/2023/05/22/2673217/0/en/Kymera-Appoints-Jeremy-Chadwick-Ph-D-as-Chief-Operating-Officer.html). He brings extensive experience in global development operations, regulatory affairs, and program management across the life sciences industry[[1]](https://www.globenewswire.com/news-release/2023/05/22/2673217/0/en/Kymera-Appoints-Jeremy-Chadwick-Ph-D-as-Chief-Operating-Officer.html). Prior to joining Kymera in May 2023, Chadwick served as Senior Vice President and Head of Global Development Office at Takeda Pharmaceuticals, where he oversaw regulatory affairs, drug safety, clinical supply chain, and global development operations[[1]](https://www.globenewswire.com/news-release/2023/05/22/2673217/0/en/Kymera-Appoints-Jeremy-Chadwick-Ph-D-as-Chief-Operating-Officer.html)[[2]](https://www.kymeratx.com/about-us/leadership/jeremy-chadwick-phd/). His career also includes senior development roles at Shire Pharmaceuticals as Group Vice President and Head of Clinical Development Operations, as well as positions at The Medicines Company, Synta Pharmaceuticals, Vertex Pharmaceuticals, and Glaxo Group Research, where he managed program management, regulatory affairs, biostatistics, and data management[[1]](https://www.globenewswire.com/news-release/2023/05/22/2673217/0/en/Kymera-Appoints-Jeremy-Chadwick-Ph-D-as-Chief-Operating-Officer.html)[[2]](https://www.kymeratx.com/about-us/leadership/jeremy-chadwick-phd/). Chadwick holds a Ph.D. and M.S. in Statistics from the University of London and a B.S. in Mathematics from De Montfort University in the United Kingdom[[1]](https://www.globenewswire.com/news-release/2023/05/22/2673217/0/en/Kymera-Appoints-Jeremy-Chadwick-Ph-D-as-Chief-Operating-Officer.html)[[2]](https://www.kymeratx.com/about-us/leadership/jeremy-chadwick-phd/). He has been instrumental in multiple successful global drug approvals across numerous therapeutic areas and previously served as chairman of the Board of Directors at Accumulus Synergy, an organization developing a data exchange platform to enhance how biopharmaceutical innovators and regulators bring medicines to patients[[1]](https://www.globenewswire.com/news-release/2023/05/22/2673217/0/en/Kymera-Appoints-Jeremy-Chadwick-Ph-D-as-Chief-Operating-Officer.html)[[2]](https://www.kymeratx.com/about-us/leadership/jeremy-chadwick-phd/). As of 2026, Chadwick owns approximately 61,202 shares of Kymera Therapeutics stock[[4]](https://www.gurufocus.com/insider/56865/jeremy-g-chadwick).

View full insider profile →

Trade Price

$85.43

Quantity

22,240

Total Value

$1,900,048.00

Shares Owned

61,202

Trade Date

Tuesday, March 31, 2026

5 days ago

SEC Filing Date

Wednesday, April 1, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Kymera Therapeutics, Inc.

Company Overview

No company information available
View news mentioning KYMR

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5286352

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime